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Abstract
Patients with non-alcoholic fatty liver disease are characterised by a decreased n-3/n-6 polyunsaturated fatty acid (PUFA)
ratio in hepatic phospholipids. The metabolic consequences of n-3 PUFA depletion in the liver are poorly understood. We
have reproduced a drastic drop in n-3 PUFA among hepatic phospholipids by feeding C57Bl/6J mice for 3 months with an n-
3 PUFA depleted diet (DEF) versus a control diet (CT), which only differed in the PUFA content. DEF mice exhibited hepatic
insulin resistance (assessed by euglycemic-hyperinsulinemic clamp) and steatosis that was associated with a decrease in
fatty acid oxidation and occurred despite a higher capacity for triglyceride secretion. Microarray and qPCR analysis of the
liver tissue revealed higher expression of all the enzymes involved in lipogenesis in DEF mice compared to CT mice, as well
as increased expression and activation of sterol regulatory element binding protein-1c (SREBP-1c). Our data suggest that the
activation of the liver X receptor pathway is involved in the overexpression of SREBP-1c, and this phenomenon cannot be
attributed to insulin or to endoplasmic reticulum stress responses. In conclusion, n-3 PUFA depletion in liver phospholipids
leads to activation of SREBP-1c and lipogenesis, which contributes to hepatic steatosis.
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Introduction
Dietary n-3 polyunsaturated fatty acid (PUFA) have important
metabolic effects due to their involvement in eicosanoid biosyn-
thesis and their ability to modulate the transcription of regulatory
genes [1,2]. Numerous in vitro and in vivo studies have
demonstrated that n-3 PUFA are able to coordinate both the
upregulation of lipid oxidation and the downregulation of lipid
synthesis. On the one hand, n-3 PUFA promote fatty acid
oxidation by binding and activating peroxisome proliferator-
activated receptor a (PPARa) [3,4]. On the other hand, n-3 PUFA
suppress lipogenesis by inhibiting sterol regulatory element
binding protein-1c (SREBP-1c) gene expression and/or activation
by proteolysis [4–6].
Several clinical studies have reported the beneficial effects of n-3
PUFA (mostly eicosapentaenoic and/or docosahexaenoic acids
from marine origin) supplementation on triglyceridemia [7], blood
pressure [8], inflammation [9] and insulin sensitivity [10].
Of interest, the western type diet is low in n-3 PUFA and brings
excessive amount of n-6 PUFA, leading to an imbalanced n-3/n-6
PUFA intake compared to the dietary recommendations. High
dietary n-6 PUFA and low dietary n-3 PUFA intake has been
suggested to promote the pathogenesis of several diseases,
including cardiovascular disease, inflammatory and autoimmune
disease [11,12]. Moreover, a lower intake in dietary sources of n-3
PUFA was suggested to be associated with non-alcoholic fatty liver
disease [13,14]. In fact, patients with hepatic steatosis present a
lower n-3/n-6 PUFA ratio in liver tissue biopsies, namely in
phospholipids subfractions, and in red blood cells [15,16]. In
accordance with this observation, rats and mice presenting a
depletion of n-3 PUFA for two generations display several features
of metabolic syndrome including hepatic steatosis [17,18].
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However, the biochemical mechanisms explaining the hepatic
alterations occurring upon n-3 PUFA depletion remain unclear.
Therefore, in the present study, we have investigated, in mice,
the effect of n-3 PUFA depletion established for 3-months on
hepatic lipid composition and metabolism using molecular and
integrative physiological approaches in vitro and in vivo. We
observed a stimulation of the hepatic lipogenic pathway, most
likely induced by the increased expression and activity of SREBP-
1c.
Results
Mice fed with a diet depleted in n-3 PUFA exhibit a
decrease in n-3 PUFA in hepatic phospholipid fractions
and changes in hepatic endocannabinoid content
DEF mice exhibited a large drop in n-3 PUFA content in
hepatic phospholipids (PLs), thereby confirming the tissue
depletion (Table 1). Despite a qualitative change in n-6 PUFA
in favour of arachidonic acid (C20:4 n-6), the total amount of n-6
PUFA in hepatic PLs was similar between both groups. The other
modification observed in DEF mice was a 51% increase in the
content of monounsaturated fatty acid (MUFA) and especially of
oleic acid (C18:1) compared to CT mice (Table 1). In accordance
with the changes in arachidonic and oleic acid, we found a higher
level of bioactive lipids belonging to the endocannabinoid system
and known to control lipogenesis, namely 2-arachidonoylglycerol
(2-AG) and N-oleoylethanolamine, in the liver of DEF mice than
in CT mice. However, for N-oleoylethanolamine it was not
significant (Table S1).
n-3 PUFA depletion decreases fatty acid oxidation and
promotes hepatic lipid synthesis, storage and secretion
Histological analysis revealed a higher number and size of lipid
droplets in the livers of DEF mice compared to CT mice
(Figure 1A). These observations were confirmed by the biochem-
ical analysis showing that lipid accumulation in the liver of DEF
mice was due to an increased hepatic content of triglycerides (TG)
and esterified cholesterol (Figure 1B).
DEF mice exhibited a higher hepatic TG secretion than CT
mice, as measured following lipoprotein lipase inhibition (tyloxapol
injection) (Figure 2A). Precision-cut liver slice (PCLS) is a model
that allows preservation of the liver lobule architecture by
maintaining cell diversity and interactions. PCLSs prepared from
fasted mice were incubated with [14C]-palmitate to measure
14CO2 release during incubation. By this method, we found that
the livers of DEF mice presented lower fatty acid oxidation
compared to those of CT mice (Figure 2B). Incubation of PCLSs
from fed CT and DEF mice with [14C]-acetate or [14C]-palmitate
showed a 40% increase in TG synthesis and FA-esterification into
TG in DEF mice compared to CT mice (Figure 2C, D).
Microarray analysis confirms a metabolic shift in favour of
fatty acid and cholesterol synthesis at the expense of
fatty acid oxidation in the livers of n-3 PUFA depleted
mice
The gene expression profiles in the livers of CT and DEF mice
were analysed by microarray in both the fasted and fed state.
Increased expression of all of the enzymes involved in fatty acid
synthesis and desaturation was observed in DEF mice compared to
CT mice in the fed and fasted states (Figure 3A and Table S2).
The statistical significance of this observation was confirmed by
analysing gene ontology with the bioinformatics tool DAVID
(Table S3). DEF mice exhibited a lower expression of several
markers of fatty acid oxidation, including PPARa and its target
genes (Figure 3A and Table S2). The bioinformatics evaluation of
transcription factor target genes among the list of genes regulated
using TFactS [19] supported the inhibition of the PPARa pathway
(Table S4).
In agreement with the physiological data, phospholipid transfer
protein (PLTP) and Apolipoprotein B (Apo B), two factors
involved in fatty acid secretion, were increased in DEF mice
when compared to CT mice (Table S2).
Increased expression of several enzymes involved in cholesterol
synthesis (from HMGCoAs to Dhcr7) and esterification for hepatic
secretion (ACAT2) also occurred in fed and fasted DEF mice
compared to CT mice (Figure 3B and Table S2). With regard to
bile acid metabolism, a higher expression of Cyp7a1 and a lower
expression of Cyp7b1 suggest a stimulation of the classic bile acid
synthesis pathway at the expense of the alternative pathway
through n-3 PUFA depletion (Figure 3B and Table S2).
SREBP-1c is involved in the metabolic alterations
occurring in the livers of n-3 PUFA depleted mice
TFactS analysis of microarray results revealed activation of
SREBPs (Table S4) but did not distinguish between SREBP-2,
SREBP-1c and SREBP-1a. Microarray analysis showed a higher
mRNA content of SREBP-1, a key transcription factor involved in
the regulation of lipogenesis, in the livers of DEF mice than in those
of CT mice (Figure 3A and Table S2). As SREBP-1c and SREBP-2
are the main forms present in the liver, it could be assumed that
Table 1. Fatty acids pattern in liver phospholipids (PLs)
fractions of CT and DEF mice.







C16:1 n-7 331.5 384.2
C18:1 n-9 1758.3 2775.8
C20:1 n-9 53.3 76.8
C18:3 n-3 52.4 0.1
C18:4 n-3 ND ND
C20:5 n-3 84.9 0.1
C22:3 n-3 ND ND
C22:5 n-3 148.6 19.2
C22:6 n-3 4612.0 1407.0
C18:2 n-6 4527.6 3314.9
C18:3 n-6 76.3 65.6
C20:2 n-6 57.1 44.6
C20:3 n-6 355.1 423.9
C20:4 n-6 6068.3 6728.7
C22:4 n-6 78.3 87.1
Data are values determined in hepatic PLs of a pool of 4 fasted mice fed with
control diet (CT) and of a pool of 4 fasted mice fed an n-3 PUFA depleted diet
(DEF) for 3 months.
ND = non detectable.
doi:10.1371/journal.pone.0023365.t001
n-3 Polyunsaturated Fatty Acid and Steatosis
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SREBP-1c was responsible for the higher SREBP-1 expression
observed by the microarray. In fact, the higher expression of
SREBP-1c and two major enzymes involved in fatty acid synthesis
(FAS and SCD-1) was confirmed by qPCR (Table S5). The western
blot analysis of SREBP-1 in the cytoplasmic and nuclear fractions
revealed a higher hepatic content of nuclear SREBP-1 at the
expense of the precursor form in the livers of DEF mice compared
to those of CT mice (Figure 4A). It should be noted that the content
of the SREBP-2 precursor and mature form were also higher in the
livers of DEF mice than in those of CT mice (Figure 4B).
Hence, we further analysed several metabolic pathways
involved in the regulation of SREBP-1c expression and activation.
Mice depleted of n-3 PUFA display hepatic insulin
resistance
Insulin induces SREBP-1c activation by enhancing SREBP-1c
transcription and proteolytic cleavage [20,21]. As shown in
Figure 5A and 5B, respectively, insulinemia and glycemia were
similar between CT and DEF mice. Following euglycemic-
hyperinsulinemic clamp, we found that DEF mice exhibited
hepatic insulin resistance as shown by the higher hepatic glucose
production upon insulin stimulation when compared to CT mice
(Figure 5C). There were no differences in the glucose infusion rate
between groups (Figure 5D). Thus, these data confirm the
development of hepatic insulin resistance in DEF mice and argue
against a role of insulin in SREBP-1c activation.
n-3 PUFA depletion does not induce hepatic
endoplasmic reticulum (ER) stress
Kammoun et al. have demonstrated that the ER stress pathway
induces SREBP-1c cleavage and expression independently from
insulin [22]. Here the microarray analysis revealed an increase in
the mRNA level of 3 markers of ER stress (Serp1, Sel1l and
GRP94) in the livers of DEF mice compared to those of CT mice
(Table S2), which was not confirmed by quantification of glucose-
regulated protein 94 (GRP94) mRNA by qPCR (Figure 6).
We also analysed by western blot and qPCR the expression of
several critical markers involved in the three axes of the unfolded
protein response (UPR), namely inositol-requiring enzyme 1a
(IRE1a), PKR-like ER kinase (PERK) and activating transcription
factor 6 (ATF6). All of the results were similar between groups, except
for glucose regulated protein 78 (GRP78) protein content which was
higher in the liver of DEF mice despite no modification in its mRNA
expression (Figure 6). These data suggest that ER stress is not involved
in the SREBP-1c activation observed in n-3 PUFA-depleted mice.
Increased Liver X receptor (LXR) activity occurs in the
livers of n-3 PUFA-depleted mice
LXR, a transcription factor involved in the prevention of
cholesterol toxicity, is able to stimulate fatty acid synthesis by
increasing the expression of SREBP-1c [21]. Microarray analysis
revealed that the mRNA content of several LXR target genes, i.e.,
PLTP, DEC1, Insig2 and Cyp7a1, were increased in the livers of
Figure 1. Accumulation of lipids in the livers of n-3 PUFA depleted mice. Oil red staining performed on frozen liver sections of fasted mice
fed a control (CT) or n-3 PUFA-depleted (DEF) diet for 3 months. Bar = 50 mm (A). TG, free cholesterol and esterified cholesterol content in the livers of
mice fed a control (CT) or n-3 PUFA-depleted (DEF) diet for 3 months. Data are the mean 6 SEM. *: mean values significantly different (P,0.05,
Student’s t-test) (B).
doi:10.1371/journal.pone.0023365.g001
n-3 Polyunsaturated Fatty Acid and Steatosis
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23365
DEF mice compared to those of CT mice. The increase of Insig2
and Cyp7a1 mRNA expression was confirmed by qPCR (Table
S5). Moreover, the expression of Cyp7b1 and Enho, which is
decreased by activated LXR, and Ncor1, an LXR inhibitor, was
reduced in DEF mice compared to CT mice (Table S2). Based on
these data, the TFactS analysis confirmed the activation of the
LXR pathway (Table S4). In addition to the microarray
expression profiling, we also measured the expression of the
ATP-binding cassette transporter ABCG5, which reflects LXR
activation, by qPCR. We found increased hepatic ABCG5 mRNA
content in DEF mice compared to CT mice (Table S5).
Altogether, these observations are in favour of an activation of
the LXR pathway upon n-3 PUFA depletion.
Discussion
Several papers suggest that decreased n-3/n-6 PUFA ratio in
the diet is associated with changes in n-3/n-6 PUFA ratio in
hepatic membrane phospholipids, on the one hand, and on the
development of hepatic steatosis in humans, on the other hand
[14-16]. Even if we can not exclude that metabolic changes of the
liver (such as oxidative stress) may contribute to changes in hepatic
fatty acid profile [15], it is conceivable that the imbalance dietary
intake of PUFA plays a crucial role in the appearance of steatosis
[14].
In a previous study, we have reported toxic steatosis in female
mice fed with n-3 PUFA depleted- sucrose rich diet for two
generations [18]. In this case, the hepatic morphological
alterations were associated with a low expression of factors and
enzymes involved in lipogenesis and an increase in the expression
of those involved in fatty acid oxidation [18]. In the present study,
we have created a model of nutritional n-3 PUFA depletion which
did not provide any signs of hepatic toxicity that could
compromise the interpretation of the metabolic data.
A targeted change in the lipid source of the diet allowed us to
create a mouse model to explore the biochemical mechanisms
underlying hepatic lipid accumulation under n-3 PUFA depletion.
As previously shown in rats [23], 3 months of dietary n-3 PUFA
depletion were sufficient to induce an altered fatty acid pattern in
hepatic PLs, characterised by a large decrease in n-3 PUFA and a
parallel increase in MUFA, without changing the total n-6 PUFA
and saturated fatty acid levels. These changes were associated with
Figure 2. n-3 PUFA depletion leads to decreased hepatic fatty acid oxidation and increased TG secretion and synthesis. Mice were
fed a control (CT) or n-3 PUFA-depleted (DEF) diet for 3 months. To measure hepatic TG secretion, fasted CT mice (closed squares, n = 4) and DEF mice
(closed circles, n = 6) were injected with tyloxapol (0.5 mg tyloxapol/g body weight). Data are the mean 6 SEM. *: mean values significantly different
(P,0.05, two-way ANOVA; for the area under the curve, P,0.05, Student’s t-test) (A). Precision-cut liver slices (PCLSs) obtained from fasted CT (n = 8)
and DEF (n = 6) mice were incubated with [14C]-palmitate for 3 hours to measure CO2 produced from fatty acid oxidation (B). TG synthesis from [
14C]-
acetate (C) and fatty acid esterification into TG from [14C]-palmitate (D) were measured in PCLSs obtained from fed CT (n = 7) and DEF mice (n = 8).
Data are the mean 6 SEM. *: mean values significantly different (P,0.05, Student’s t-test).
doi:10.1371/journal.pone.0023365.g002
n-3 Polyunsaturated Fatty Acid and Steatosis
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Figure 3. n-3 PUFA-depleted mice exhibited higher mRNA content of enzymes involved in fatty acid and cholesterol synthesis. n-3
PUFA depletion induces increased hepatic expression of enzymes involved in lipogenesis (A) and cholesterol synthesis (B). Microarray analysis was
performed on a pool of RNA obtained from fasted mice fed a control (CT) or n-3 PUFA-depleted (DEF) diet for 3 months. In red are depicted enzymes
n-3 Polyunsaturated Fatty Acid and Steatosis
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hepatic accumulation of TG and esterified cholesterol, leading to a
mixed macro- and microvesicular steatosis.
The microarray analysis revealed a reduced expression of
PPARa and its target genes in the livers of DEF mice compared to
those of CT mice. Moreover, PCLSs prepared from fasted DEF
mice had a reduced conversion of palmitate into CO2 when
compared to PCLSs from CT mice. Therefore, the decreased fatty
acid oxidation observed in n-3 PUFA-depleted mice may
contribute to hepatic steatosis. The in vitro studies using PCLS
also revealed a higher capacity to synthesise fatty acids and TG
from labelled precursors in the livers of DEF mice compared to
those of CT mice. Microarray analysis confirmed a higher
expression of all the enzymes involved in fatty acid synthesis in
the livers of DEF mice compared to those of CT mice. The SCD-1
overexpression found in DEF mice could explain the increased
MUFA content in hepatic PLs and, to a certain extent, the
enhanced liver TG secretion observed under n-3 PUFA depletion,
as an increased SCD-1 expression is associated with higher liver
TG secretion in mice [24]. Numerous studies, both in vitro and in
vivo, have demonstrated that n-3 PUFA supplementation
decreases lipid synthesis [2] through inhibition of SREBP-1c gene
expression and/or through the inhibition of the translocation of
the active form of SREBP-1c in the nucleus [4–6,25]. The ER
protein Insig2a keeps SREBP-1c inactive at the ER membranes,
Figure 4. n-3 PUFA depletion leads to hepatic SREBP-1 and SREBP-2 activation. Liver immunoblot analysis of the hepatic SREBP-1
precursor (pSREBP-1) and nuclear (nSREBP-1) form (A) and of the hepatic SREBP-2 precursor (pSREBP-2) and nuclear (nSREBP-2) form (B) from fasted
mice fed a control (CT; n = 6) or n-3 PUFA depleted (DEF; n = 7) diet for 3 months. Quantification of immunoblots is shown at right. Data are the mean
6 SEM. *: mean values significantly different (P,0.05, Student’s t-test).
doi:10.1371/journal.pone.0023365.g004
and factors for which mRNA content in the liver of DEF mice was higher and in green those for which mRNA content was lower, than the values
measured in CT mice in the fasted state. The color bare refers to the log2 fold change in DEF mice versus value obtained in CT mice. No threshold was
applied on the fold change. We applied a statistical significance threshold calculated by the MAS5 algorythm as recommended by the manufacturer
(Affymetrix). EC = esterified cholesterol. See Table S2 for raw data.
doi:10.1371/journal.pone.0023365.g003
n-3 Polyunsaturated Fatty Acid and Steatosis
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23365
and some studies have reported that Insig2a overexpression leads
to a reduction of SREBP-1c activation [26]. In our study, we
showed that SREBP-1c expression and the nuclear level of the
SREBP-1 protein both increased despite a higher Insig2a
expression.
Insulin is considered to be the classical driver of SREBP-1c
activation, which largely explains carbohydrate-induced lipogen-
esis [20]. In DEF mice, we observed no changes in glycemia and
insulinemia. Euglycemic-hyperinsulinemic clamp revealed a lower
inhibitory effect of insulin on hepatic glucose production in DEF
mice compared to CT mice. These results demonstrate that n-3
PUFA depletion promotes hepatic insulin resistance. Therefore,
SREBP-1c activation may be driven by an insulin-independent
pathway.
A recent study has suggested that the increased lipogenesis
observed in an insulin-resistant state could result from ER stress
[22]. To maintain ER function when the secretory pathway is
compromised, cells have developed an adaptive mechanism called
UPR [27,28]. Activation of the UPR pathway occurs together with
activation of SREBP-1c in the livers of obese ob/ob mice and in
nutritional models of steatosis such as hyperhomocysteinaemia or
alcohol-fed rodents [22,29,30]. IRE1a, ATF6 and PERK are
three proximal sensors of ER stress [27,28]. Some studies have
pointed out the importance of IRE1a/X-box binding protein-1
(XBP-1) and PERK pathways activation for the stimulation of
lipogenesis in genetic deletion models [31]. Here we did not
observe any modifications in the expression and/or the protein
content of PDI, GRP94, EDEM1, unspliced XBP-1, spliced XBP-
1 or CHOP, all involved in the 3 branches of the UPR. Moreover,
eukaryotic translation initiation factor 2a (eIF2a) phosphorylation
was similar between groups. Of note, ER stress is also associated
with lower Apo B and hepatic TG secretion [31]. Here we found
that TG secretion was increased upon n-3 PUFA depletion.
Foufelle’s group has demonstrated that GRP78 overexpression in
the liver of ob/ob mice could inhibit SREBP-1c proteolytic
cleavage [22]. Curiously, we observed an increased SREBP-1c
activation in the liver of DEF mice despite a higher hepatic
GRP78 protein content. Altogether, these results provide evidence
against the involvement of ER stress in the hepatic lipid
metabolism alterations occurring in n-3 PUFA-depleted mice.
LXR is another nuclear factor involved in the regulation of fatty
acid synthesis [32]; it is required for the full induction of the
SREBP-1c promoter by insulin [33,34]. Microarray analysis and
qPCR quantification of LXR target gene expression suggested
increased activity of LXR in the livers of DEF mice compared to
those of CT mice. Additionally, DEF mice exhibited reduced
expression of Ncor1, a major LXR corepressor [35]. The
increased LXR activity observed here could be due to the
decrease in tissue n-3 PUFA content. Indeed, studies have
reported that n-3 PUFA can inhibit the natural binding of
oxysterols, the endogenous LXR ligands, to the receptor, leading
to decreased SREBP-1c gene transcription [36–39]. Other studies
have reported that n-6 PUFA, especially arachidonic acid, can also
inhibit LXR activity [40]. However, this does not seem to be the
case here, as total n-6 PUFA content was similar and arachidonic
acid (C20:4) content was even higher in hepatic PLs of DEF mice
than in those of CT mice.
Higher cholesterol content has also been observed in the livers
of DEF mice, and it is associated with an increased expression of
enzymes involved in cholesterol synthesis and an activation of
Figure 5. n-3 PUFA-depleted mice exhibited hepatic insulin resistance. Insulinemia (A) and glycemia (B) in fasted mice fed a control (CT;
n = 6) or n-3 PUFA-depleted (DEF; n = 7) diet for 3 months. Hepatic glucose production (C) and glucose infusion rate (D) were measured during
steady-state euglycemic-hyperinsulinemic clamp performed on fasted mice fed a control (CT; n = 4) or n-3 PUFA depleted (DEF; n = 6) diet for 3
months. Data are the mean 6 SEM. *: mean values significantly different (P,0.05, Student’s t-test).
doi:10.1371/journal.pone.0023365.g005
n-3 Polyunsaturated Fatty Acid and Steatosis
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SREBP-2. Some authors have suggested that cholesterol over-
loading leads to LXR activation through the production of 27-
hydroxycholesterol [41] or of 24(S),25-epoxycholesterol, which is
derived from a shunt in the cholesterol biosynthetic pathway [42].
LXR activation is also dependent on the expression of Cyp7b1, an
enzyme involved in the alternative bile acid synthesis pathway that
degrades oxysterols [43,44]. Interestingly, expression of Cyp7b1
was lower in the livers of DEF mice than in those of CT mice.
Thus, our data suggest that n-3 PUFA depletion promotes the
production of endogenous LXR ligands and that this increase
could in turn enhance LXR activity in the liver. The increased
LXR activity might also contribute to the higher hepatic TG
secretion observed in n-3 PUFA-depleted mice, as LXR ligands
have been shown to induce Apo B-dependent TG secretion by
increasing PLTP expression in mice [45].
Of note, we found that DEF mice exhibited a higher hepatic
content of 2-AG than CT mice, which could result from the lower
expression of monoacylglycerol lipase (MGL). This enzyme is
indeed mostly involved in 2-AG catabolism (Table S2). It has been
shown that n-3 PUFA depletion elevates and n-3 PUFA
supplementation reduces the 2-AG level in the brain of mice
[46]. A few papers suggest that the endocannabinoids, 2-AG being
classified among them, are bioactive lipids involved in the
regulation of the hepatic lipid homeostasis [47]. Indeed, it has
been reported that CB1 endocannabinoid receptor activation in
mice induces SREBP-1c and its target lipogenic enzymes such as
FAS in the liver and in the adipose tissue [48,49]. In hepatic
stellate cells an increased 2-AG level is associated with increased
SREBP-1c expression and lipogenesis [50]. Therefore, we
speculate that the increase in 2-AG content might also influence
the higher SREBP-1c expression occurring in DEF mice.
Carbohydrate-responsive element-binding protein (Chrebp) is
another key transcription factor involved in the regulation of
lipogenic gene expression [51]. It has been reported that n-3
PUFA could inhibit the lipogenesis by inhibiting SREBP-1c
pathway, but also by altering Chrebp translocation to the nucleus
[52,53]. Our data revealed no difference between CT and DEF
mice in hepatic Chrebp mRNA content. However, we found in
the liver of DEF mice an increased in L-PK expression (Table S2,
S5), which constitute on target gene of Chrebp. Therefore, we can
not rule out a potential implication of Chrebp in the inhibitory
effect of n-3 PUFA on lipogenesis, even if its contribution remains
less clear than the one of SREBP-1c.
In conclusion the metabolic characteristics observed in our
model of n-3 PUFA depletion are opposite to the ones occurring
upon n-3 PUFA supplementation [2]. The consumption of a diet
containing low levels of n-3 PUFA for 3 months was sufficient to
induce hepatic n-3 PUFA depletion in PLs, steatosis (despite the
maintenance of VLDL secretion process) and insulin resistance.
Decreased fatty acid oxidation and increased TG and cholesterol
synthesis both contributed to lipid accumulation. The activation of
SREBP-1c-related pathways was particularly interesting, as it
occurred in a hepatic insulin-resistant state and independently of
ER stress, and it is consistent with increased LXR activity and a
higher endocannabinoid ligand level (2-AG) (Figure 7). Even if we
may not directly extrapolate our experimental data obtained in
mice to human health, it is interesting to note, in accordance with
our experimental data, that human biopsies of non-alcoholic fatty
liver disease patients are characterized by an increased expression
of SREBP1c and decreased expression of PPARa and this was
associated with n-3 PUFA depletion [54]. Our results provide new
insights into the effect of nutritional disequilibrium at the expense
of n-3 PUFA on the occurrence of steatosis.
Materials and Methods
Ethics statement
The animal experiments were reviewed and approved by the
local ethic committee; the agreement of the animal experiments
performed in this study was given by the ethical committee for
animal care of the Health Sector of the Universite´ catholique de
Louvain, under the supervision of prof. P. Gianello P et JP Dehoux
under the specific number ULC/MD/2007/003. Housing condi-
tions were as specified by the Belgian Law of 14 November, 1993 on
the protection of laboratory animals (agreement nu LA 1230314).
Animals and diets
Male C57Bl/6J mice (9 weeks old; Charles River, Brussels,
Belgium) were housed in groups of 4 mice per cage at 22uC in a
12 h light/dark cycle and given free access to diet and water.
After an acclimatisation period of 1 week, mice were fed a
control (CT) (D08041805, Research Diets, New Brunswick, USA)
or an n-3 PUFA-depleted diet (DEF) (D08041806, Research Diets,
New Brunswick, USA) for 3 months ad libitum. The n-3 PUFA
depletion was induced by replacing the soybean oil with sunflower
oil; all other nutrients including MUFA and saturated fatty acid
content were similar to those of the CT diet (Table S6, S7).
At the end of the study period, mice were anaesthetised
(ketamine/xylazine i.p., 100 and 10 mg/kg of body weight,
respectively) after a 6 h fasting period (CT, n= 6; DEF, n= 7).
All biochemical measurements, qPCR, western blot and micro-
array analysis were performed on these fasted mice. For
comparison with the results obtained in the fasted state,
microarrays were also run using fed mice (CT, n= 4; DEF,
n = 7). In addition, other mouse experiments were conducted for
in vivo measurement of hepatic TG secretion, euglycemic-
hyperinsulinemic clamp studies and PCLS assessment of hepatic
fatty acid oxidation and TG synthesis. Except for the latter, these
studies were carried out in fasted mice.
Blood biochemical analysis
Blood glucose was determined before anaesthesia with a glucose
meter (Roche diagnostic) on 3.5 ml of blood collected from the tip
of the tail vein. Vena cava blood samples were collected in EDTA
tubes. After centrifugation (3 min at 13000 g), plasma was stored
at 280uC until analysis. Insulin was measured in 5 ml of plasma
using an ELISA kit (Mercodia, Upssala, Sweden).
Liver histological analysis
For the detection of neutral lipids, frozen sections obtained from
a fraction of the main liver lobe mounted in embedding medium
Figure 6. Absence of hepatic ER stress under n-3 PUFA depletion. Mice were fed a control (CT; n = 6) or n-3 PUFA-depleted (DEF; n = 7) diet
for 3 months. The hepatic mRNA content of glucose-regulated protein 78 (GRP78), glucose-regulated protein 94 (GRP94), protein disulfide isomerise
(PDI), C/EBP homologous protein (CHOP), ER degradation enhancer, mannosidase alpha-like 1 (EDEM1), unspliced (uXBP-1) and spliced (sXBP-1) X-box
binding protein-1 is shown from fasted CT and DEF mice. The qPCR results were analysed according to the 22DD ct method and were normalised to
RPL-19 mRNA (A). Immunoblot analysis of GRP78, PDI, GRP94 and total and phosphorylated eukaryotic translation initiation factor 2a (eIF2a) (B) in the
livers from fasted CT and DEF mice. Quantification of immunoblots is shown below. Data are the mean 6 SEM. *: mean values significantly different
(P,0.05, Student’s t-test).
doi:10.1371/journal.pone.0023365.g006
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(Tissue-tek, Sakura) were sliced and stained with the oil red O,
using 0.5% oil red O dissolved in propylene glycol for 10 min at
60uC. The sliced sections were then counterstained.
Tissue biochemical analysis
The remaining liver tissue after histological sampling was
immediately clamped in liquid N2 and kept at 280uC until
analysis. Fatty acid content was determined in tissue PLs of a pool
of 4 mice per group as reported before [55]. For hepatic lipid
content measurement, lipids were extracted with chloroform-
methanol (2:1) according to Folch et al. [56]. TG, total and free
cholesterol concentrations were measured using kits (Diasys
Diagnostic and Systems, Holzheim, Germany) coupling enzymatic
reaction and spectrophotometric detection of reaction end-
products. Esterified cholesterol was calculated as the subtraction
between total cholesterol and free cholesterol.
Measurement of endocannabinoids levels
Liver tissues were homogenized in CHCl3 (10 ml) and 200 pmol
of each deuterated standard (d-AEA, d-OEA, d-PEA, d-SEA, d-2-
AG) were added. MeOH (5 ml) and H2O (2.5 ml) were then
added and the lipids extracted by vigorous mixing. Following
centrifugation, the organic layer was recovered, dried under a
stream of N2 and purified by solid phase extraction using silica and
eluted with EtOAc-Acetone (1:1) [57,58]. The resulting lipid
fraction was analyzed by HPLC-MS using a LTQ Orbitrap mass
spectrometer (ThermoFisher Scientifc) coupled to an Accela
HPLC system (ThermoFisher Scientific). Analytes separation was
achieved using a C-18 Supelguard pre-column and a Supelcosil
LC-18 column (3 mM, 46150 mm) (both from Sigma-Aldrich).
Mobile phase A and B were composed of MeOH-H2O-acetic acid
75:25:0.1 (v/v/v) and MeOH-acetic acid 100:0.1 (v/v), respec-
tively. The gradient (0.5 ml/min) was designed as follows: from
100% A to 100% B in 15 min, followed by 10 min at 100% B and
subsequent re-equilibration at 100% A. MS analysis in the positive
mode was performed by APCI ionization with the capillary and
APCI vaporizer temperatures set at 250uC and 400uC, respec-
tively [49]. Endocannabinoids were quantified by isotope dilution
using its deuterated standard (showing identical retention times).
The calibration curves were generated as described [57] and the
data normalized by tissue sample weight.
cDNA microarray analysis
Total RNA was isolated from liver tissue of fasted and fed mice
using the TriPure reagent (Roche, Basel, Switzerland). RNA
quality was checked using Bioanalyzer (Agilent). Equal amounts
RNA from each mice (n = 4 to 7 mice per group) were pooled
within each group. Microarray experiments were performed as
described [59,60]. Double-stranded cDNA was synthesized from
total RNA using the One-cycle cDNA synthesis kit (Affymetrix,
Santa Clara, USA). Biotin-labeled cRNA was synthesized using
GeneChip IVT labelling kit (Affymetrix, Santa Clara, USA). After
fragmentation, cRNA was hybridized to mouse genome 430 2.0
array (Affymetrix, Santa Clara, USA). The MAS5 algorithm was
run using GCOSH Affymetrix software as follows: the scaling
factor using all probe sets was set to 100, the normalize factor was
set to 1 and the baseline comparison was done on the CT diet
hybridization samples. Probe sets that were ‘absent’ or ‘NC’ in the
four conditions were eliminated. Then, only genes marked as
significantly ‘Increased’ or ‘Decreased’ upon n-3 PUFA depletion
in both fasted and fed mice were considered as the regulated gene
list.
Figure 7. Proposed metabolic pathways involved in fatty acid and cholesterol accumulation in the livers of n-3 PUFA depleted
mice. The reduction of fatty acid oxidation and the induction of lipogenesis both contribute to the accumulation of lipids in the livers of n-3 PUFA-
depleted mice. The reduced fatty acid degradation could result from the inhibition of the PPARa pathway. De novo lipogenesis is promoted through
SREBP-1c activation. Data suggest that SREBP-1c activation could result from both increased hepatic 2-AG content and LXR activation. The lower n-3
PUFA content in hepatic phospholipids can lead to higher 2-AG production, which could therefore stimulate CB1 and then SREBP-1c expression. Both
hepatic n-3 PUFA depletion and higher cholesterol content contribute to LXR activation. Increased SREBP-2 activation, occurring by an unknown
mechanism, could play a role in the increased cholesterol synthesis observed in the n-3 PUFA-depleted livers.
doi:10.1371/journal.pone.0023365.g007
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The regulated gene list was submitted to the DAVID web server
for functional enrichment analysis against ontologies such as: Gene
Ontology (GO), Kegg pathways and SwissProt PIR (SP-PIR)
keywords. We considered a P-value threshold of 0.05 as
significant.
TFactS predicts transcription factor regulation form gene lists
based on the comparison with a database of experimentally-
validated target genes. The regulated gene list was submitted to
TFactS (www.tfacts.org). Only transcription factors with at least 10
target genes in signature were analysed. We considered an E-value
,0.05 as significant. All data are MIAME compliant and the raw
data has been deposited in a MIAME compliant database; the
GEO database (accession number GSE26986).
Real-time quantitative PCR
cDNA was prepared by reverse transcription of 1 mg total RNA
using the Kit Reverse transcription System (Promega, Leiden, The
Netherlands). Real-time qPCRs were performed with a StepOne-
PlusTM instrument and software (Applied Biosystems, Foster City,
CA, USA) using Mesa Fast qPCRTM (Eurogentec, Seraing,
Belgium) as described [18]. Primers and gene details are
summarized in Table S8.
SDS/PAGE and immunoblotting
For total lysates, approximately 30 mg of frozen liver were
homogenized with TissueLyser II (Qiagen) in RIPA buffer
(25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1%
deoxycholic acid, 0.1% sodium dodecyl sulphate) supplemented
with a cocktail of protease inhibitors (P8340, Sigma-Aldrich, Saint
Louis, USA) and of phosphatase inhibitors (Calbiochem, Notting-
ham, UK). The homogenates were then centrifuged for 20 min at
13000 g. Cytoplasmic and nuclear proteins were extracted
following manufacturer’s instruction (NE-PERH, Thermo Scien-
tific, Waltham, USA) from 50 mg of liver tissue. Equal amount
proteins were separated by SDS/PAGE and transferred to
nitrocellulose membrane. The membranes were incubated
overnight at 4uC with the following antibodies diluted in tris-
buffered saline tween-20 containing 1% non fat dry milk: GRP78
(1:1000), GRP94 (1:1000), PDI (protein disulfide isomerise,
1:1000), total eIF2a (1:500), SREBP-2 (1:200) and SREBP-1
(1:1000). P-eIF2a (1:1000) was diluted in tris-buffered saline
tween-20 without non fat dry milk. All antibodies were purchased
from Abcam except GRP94, GRP78 and PDI (Cell signalling,
Danvers, USA). GAPDH and b-actin (Abcam, Cambridge, UK)
were used as loading control. The films were quantified using
ImageJ software.
Hepatic fatty acids synthesis, esterification and oxidation
For fatty acid synthesis and esterification, precision-cut liver
slices (PCLS) were prepared with a Krumdieck Tissue Slicer from
CT (n= 7) and DEF (n= 8) fed mice according to a procedure
previously described [61]. PCLS were preincubated 30 minutes in
ice cold Waymouth medium supplemented with insulin (0.1 mM),
penicillin/streptomycin (1%) and bovine serum albumin (0.3%).
After 30 minutes of preincubation, PCLS were transferred into
Waymouth medium (supplemented with 0.1 mM insulin, 1%
penicillin/streptomycin and 0.1% bovine serum albumin) con-
taining 2 mM [14C]-acetate (0.2 mCi/mmol) or 0.2 mM [14C]-
palmitate (0.2 mCi/mmol) and incubated for 3 h. Incubations
were carried out at 37uC under an atmosphere of O2/CO2
(95:5%) in a shaking water-bath. PCLS were sonicated in 0.4 ml
NaCl (0.9%) before the addition of 2.5 ml of isopropanol/heptane
(4:1) for TG extraction. After 1 h of incubation at room
temperature, 1.5 ml of heptane and 1 ml of water were added
to the samples. For slices incubated with palmitate, the organic
phase was rinsed two times with NaOH 1N/water/ethanol
(5:45:50). TG collected from the upper organic phase was counted
in 10 ml scintillation fluid (Ultima Gold) in a beta Wallac-1410
counter.
For fatty acid oxidation, PCLS were prepared from CT (n= 8)
and DEF (n = 6) fasted mice. After 30 minutes of preincubation,
PCLS were incubated in Waymouth medium (supplemented with
0.1 mM insulin, 1% penicillin/streptomycin and 0.1% bovine
serum albumin) containing 0.2 mM [14C]-palmitate (0.4 mCi/
mmol) for 3 h at 37uC in a shaking water-bath. Flasks were gassed
with O2/CO2 (95:5) and sealed with rubber caps equipped with
suspended plastic center wells, containing 400 ml of NaOH 10%.
Incubations were terminated by addition of 1 ml of HCLO4 5%.
Control flasks were acidified immediately prior to addition of liver
slices. To trap the 14CO2, an additional 60 min of shaking was
allowed. To determine the amount of produced CO2, all the
NaOH was counted in 10 ml scintillation fluid.
Hepatic triglycerides secretion
Following a 4 h fasting period, CT (n= 4) and DEF (n = 6) mice
were injected with a 10% solution of Tyloxapol (0.5 mg of
Tyloxapol/g body weight) (T0307-5G, Sigma-Aldrich, Saint
Louis, USA) through the tail vein to inhibit TG degradation by
lipoprotein lipase. Plasma samples were collected through the tail
vein before the injection (0 min) and 30, 60, 90 and 120 minutes
after Tyloxapol injection. TG in plasma was measured using
Diasys Diagnostic and Systems kit (Holzheim, Germany).
Euglycemic-Hyperinsulinemic clamp study
Mice were anesthetized with isoflurane (Abbott, Rungis, France)
and a catheter was indwelled into the femoral vein as previously
described [62]. Then, mice were housed individually and were
allowed to recover for 10 days. Hepatic Insulin sensitivity was
assessed by the euglycemic-hyperinsulinemic clamp as described
[62,63]. Mice (CT n=4; DEF n=6) fasted for 5 h, were infused
with human insulin (Actrapid) at a rate of 2.5 mU ? kg21 ? min21
for 3 h and d-(3H)3-glucose (Perkin Elmer, Boston, MA) was
infused at rate of 0.33 mCi ? min21 to ensure a detectable plasma
d-(3H)3-glucose enrichment. Throughout the infusion, tail blood
glycemia was assessed every 10 min using a blood glucose meter
(Accu-chek, Aviva, Roche). Euglycemia was maintained by
periodically adjusting a variable infusion of 20% (wt/vol) glucose.
When the steady-state was obtained, plasma glucose concentra-
tions and d-(3H)3-glucose specific activity were determined in 5 ml
of blood sampled from the tip of the tail vein every 10 min during
the last hour of the infusion.
Statistical analysis
Results are presented as mean 6 SEM. Statistical significance
was assessed by a Student t-test or Two-way ANOVA using
GraphPad Prism version 4.00 for Windows. P,0.05 was
considered as statistically significant.
Supporting Information
Table S1 Endocannabinoids content in the liver of CT
and DEF mice. 2-arachidonoylglycerol (nmol/g liver tissue), N-
arachidonoylethanolamine (pmol/g liver tissue), N-palmitoyletha-
nolamine (pmol/g liver tissue), N-stearoylethanolamine (pmol/g
liver tissue) and N-oleoylethanolamine (pmol/g liver tissue) content
in the liver of fasted mice fed with a control (CT; n = 6) or n-3
PUFA depleted diet (DEF; n = 7) for 3 months. Data are the
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mean 6 SEM. *: mean values significantly different (P,0.05,
Student t-test)
(DOC)
Table S2 Genes significantly modulated in the liver of
n-3 PUFA depleted mice (DEF) compared to control mice
(CT). Genes significantly up (positive values) or downregulated
(negative values) in the liver of mice fed with an n-3 PUFA
depleted (DEF) diet for three months compared to mice fed with a
control (CT) diet in the fasted and fed state. Results are obtained
from microarray analyses and are expressed as Log2 of the fold
changes in DEF versus CT values. NC = not significantly
changed between CT and DEF mice.
(DOC)
Table S3 Pathway and gene ontology analysis using
DAVID. The consensus list of regulated genes was submitted to
DAVID. Terms that were significantly represented (corrected P-
values and FDR ,0.05) are shown. Redundant terms were
removed.
(DOC)
Table S4 Transcription factor predictions by TFactS.
The list of genes changed in n-3 PUFA depleted mice compared to
control mice (in the fed and starved conditions) was submitted to
TFactS (sign-less) using default settings. Transcription factors that
are significantly regulated with P-value, E-value, Q-value, FDR
and random control ,5% are shown. The regulation type
(activation or inhibition) is indicated if it was found significant
(p,0.05) by TFactS (sign-sensitive). HNF4 is not present in the
latter database. Only transcription factors with a minimum of 10
target genes in signature were analysed.
(DOC)
Table S5 qPCR confirmation of genes modulated in the
liver of n-3 PUFA depleted mice (DEF) compared to
control mice (CT). mRNA content of sterol-regulatory-
element-binding protein-1c (SREBP-1c), fatty acid synthase
(FAS), stearoyl-CoA desaturase-1 (SCD-1), ATP-binding cassette
transporters G5 (ABCG5), insulin induced gene 2a (Insig2a),
carbohydrate-responsive element-binding protein (Chrebp), liver-
pyruvate kinase (L-PK), cytochrome P450, family 7, subfamily A,
polypeptide 1, (cyp7a1) and 3-hydroxy-3-methyl-glutaryl-CoA
reductase (HMGCoAr) in the liver of mice fed a control (CT; n
= 6) or n-3 PUFA depleted diet (DEF; n = 7) for three months.
Results were analysed according to the 22DD ct method and were
normalised to RPL-19 mRNA. Data are the mean 6 SEM.
*: mean values significantly different (P,0.05, Student t-test)
(DOC)
Table S6 Composition of control (CT) and n-3 PUFA
depleted (DEF) diet. Formulated by Research Diets. Paren-
thetical numbers indicate the manufacturer’s diet number.
(DOC)
Table S7 Fatty acid composition of soybean and
sunflower oil. Fatty acid composition of soybean and sunflower
oil used for the CT and DEF diet respectively.
(DOC)
Table S8 Primers sequences used for real-time quanti-
tative PCR. RPL19; ribosomal protein L19, FAS; fatty acid
synthase, SREBP-1c; sterol-regulatory-element-binding protein-
1c, Chrebp; carbohydrate-responsive element-binding protein, L-
PK; liver-pyruvate kinase, SCD-1; stearoyl-CoA desaturase-1,
ATP-binding cassette transporters G5; ABCG5, cyp7a1; cyto-
chrome P450, family 7, subfamily A, polypeptide 1, Insig2a;
insulin induced gene 2a, HMGCoAr; 3-hydroxy-3-methyl-gluta-
ryl-CoA reductase, EDEM1; ER degradation enhancer, manno-
sidase alpha-like 1, spliced (s) and unspliced (u) XBP-1; X-box
binding protein 1, GRP78; glucose-regulated protein 78, GRP94;
glucose-regulated protein 94, CHOP; CCAAT/enhancer binding
protein homologous protein, PDI; protein disulfide isomerise.
(DOC)
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